Portage Biotech Inc. (“Portage” or the “Company”) wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review.
August 28, 2018
· 1 min read